Please login to the form below

Not currently logged in
Email:
Password:

King Pharmaceuticals

This page shows the latest King Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.

Latest news

  • Opioid analgesics

    The initial development of this immediate-release tamper-resistant formulation, formally known as Acurox, was under collaboration with Acura and King Pharmaceuticals. ... As part of the research programme initiated by King Pharmaceuticals (now Pfizer)

  • Burton Paul appointed to 1HQ’s health division

    Paul brings more than 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. ... His work includes brand delivery for some of the biggest names in the sector, most notably: Adcock Ingram,

  • Lipitor losses affect Pfizer's Q2 sales

    Sales were aided by the purchase of King Pharmaceuticals, with Pfizer gaining an extra $357m in sales.

  • FDA approves Pfizer's pain drug

    Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.

  • Survival strategy

    Marketed products. The M&A strategy in 2010 was reflected in Pfizer's acquisition of King Pharmaceuticals for $3.6bn announced in October and Astellas' acquisition of OSI Pharmaceuticals for $4bn ... Nevertheless there were a few deals in 2010, such as

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics